sameAs
Quinine vs. Artemether/Lumefantrine in Uncomplicated Malaria During PregnancyMulti-Centre Trial Comparing Three Artemisinin-Based Combination Treatments on P. Falciparum MalariaEffectiveness of Artemether-Lumefantrine for Malaria Treatment of Children at Community Level in TanzaniaACT MALI: Treatment of Malaria Based on Combination TherapiesOtotoxicity of Artemether / Lumefantrine (Coartem) and Other AntimalarialsChloroquine and Coartem for Treatment of Symptomatic Children With Plasmodium Falciparum in Guinea BissauPyronaridine Artesunate (3:1) Versus Coartem® in P Falciparum Malaria PatientsEvaluation of Potential Effect of Artemether - Lumefantrine and Malaria Drugs on Auditory FunctionRandomized Trial on Effectiveness of ACTs in GhanaSafety Study on the Effect of Eurartesim™ on QT/QTc Interval Compared to Riamet in Healthy VolunteersDihydroartemisinin- Piperaquine Versus Artemether- Lumefantrine in the Treatment Uncomplicated Plasmodium Falciparum Malaria in SudanArtemether-Lumefantrine (AL) Unit Dose Pre-packs Versus Blister PacksArtemisinin-based Combination Therapy-Intermittent Preventive Treatment (ACT-IPT) Trial Among Schoolchildren in Kassena-Nankana, GhanaTrial of Malaria Seasonal IPTc Combined With Community Case ManagementP. Knowlesi Trial of Artemether-lumefantrine vs ChloroquineParasite Clearance Time and Time to Recurrent Infection Following Treatment With Artemether/LumefantrineAdherence to Antimalarial Drugs in Sierra LeoneTreatment Efficacy and Malaria TRANSmission After Artemisinin Combination Therapy (TRANSACT)Pharmacokinetic Interaction Between the Antimalarial Combination Artemether/Lumefantrine and Combination Antiretroviral Therapy Including Lopinavir/Ritonavir in HIV-infected AdultsEfficacy of Artesunate + Amodiaquine Versus Artemether-lumefantrine for Falciparum Malaria in Zanzibar, 2005Tolerability and Efficacy of Artemether-Lumefantrine Versus Artesunate + Amodiaquine in ZanzibarReducing the Burden of Malaria by Targeting Hotspots of Malaria TransmissionAnti-parasitic Activity and Safety Assessment of SAR97276A in Children With Uncomplicated MalariaTracking Resistance to Artemisinin (TRAC)Efficacy of Artemether-lumefantrine, Artesunate-amodiaquine and Dihydroartemisinin-piperaquine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in MalawiExtended Duration Artemether-lumefantrine Treatment for Malaria in ChildrenComparison of Arterolane-piperaquine Versus Arterolane-piperaquine+Mefloquine Versus Artemether-lumefantrine in Kenyan ChildrenEfficacy And Safety Of AL For The Treatment Of Uncomplicated Falciparum Malaria In Mainland TanzaniaTargeted Active Case Detection Among High Risk Populations in Southern Lao Peoples Democratic RepublicImpact of Artemisinin-based Combination Therapy and Quinine on Treatment Failure and Resistance in Uncomplicated MalariaArtemether-lumefantrine Resistance Monitoring in Children With Uncomplicated Plasmodium Falciparum Malaria in MaliSurveillance of Effectiveness/Safety of Artemether-lumefantrine in Patients With MalariaA Community Setting Study of Malaria After Systematic Treatment of Symptomatic Carriers of P. Falciparum With COA566 (Coartem®)Antioxidant Micronutrients in MalariaEfficacy of Artemisinin Combination Therapies for the Treatment of Uncomplicated P. Vivax in Pregnancy in Brazil (PAACT-PV)Safety and Effectiveness of Artemisinin-based Combination Therapies (ACTs) With Repeated Treatments for Uncomplicated Falciparum Malaria Over a Three-year PeriodSeasonal Malaria Chemoprevention Versus Home Management of Malaria in Children Under 5 Years in GhanaEfficacy of Three ACTs for the Treatment of Falciparum Malaria in Maradi NigerArtemether/Lumefantrine and Vivax MalariaEfficacy, Safety and Pharmacokinetics of Artemether-lumefantrine Dispersible Tablet in the Treatment of Malaria in Infants < 5 kg
P4844
Structure-activity relationships of novel anti-malarial agents: part 5. N-(4-acylamino-3-benzoylphenyl)-[5-(4-nitrophenyl)-2-furyl]acrylic acid amides.Structure-activity relationships of novel anti-malarial agents. Part 6: N-(4-arylpropionylamino-3-benzoylphenyl)-[5-(4-nitrophenyl)-2-furyl]acrylic acid amides.Structure-activity relationships of novel anti-malarial agents. Part 7: N-(3-benzoyl-4-tolylacetylaminophenyl)-3-(5-aryl-2-furyl)acrylic acid amides with polar moieties.Susceptibility of Plasmodium falciparum to artemisinins and Plasmodium vivax to chloroquine in Phuoc Chien Commune, Ninh Thuan Province, south-central VietnamDrug Interactions between Dolutegravir and Artemether-Lumefantrine or Artesunate-Amodiaquine
P921
Q61917560-B4809BA8-1C85-43C2-9651-2B129E6F13D4Q61918559-782EDE81-EA48-4595-8871-6DC727313A6FQ61920671-0FC08FF7-52AA-4F95-9C4E-6B7EC20DDB7FQ61920835-74159527-735D-4817-9417-F8547B7104E4Q61920986-9F9D586D-9366-4122-A5BD-D076C5737D30Q61921434-60D215FD-3B35-45BA-9C0E-6CD1FC4EC855Q61921811-82FFBE58-3A26-44CD-A571-868FF7FE091AQ61924784-AA49AF43-C64A-4229-AC91-C862BA294FE0Q61932617-4682DECF-C2E9-4451-81F8-E4D4E0FDAAA5Q61935753-4E0224CB-9F6F-4265-BC5D-DA514F8AC0E7Q61938184-9AD74998-4D2E-40BB-9E61-4E50B32B556FQ61939403-0894D7AB-4D4B-471A-B157-C59703F4EF74Q61965810-CECB3BB7-04BB-420D-8070-6A6BB960AC9FQ61967660-5944AD1C-01C0-45A5-AB5A-BA9D0AC595A4Q61969244-92CFAD02-135F-4EC0-8400-09905B57173AQ61969458-8A6680F8-154D-428F-9524-C2EC61250EC3Q61975589-F240C0B7-5779-4D86-AC1E-44F97F83F120Q61980691-A3D28DE4-C5DD-4EF7-AFD9-7813CB740C7DQ61980702-9D065872-DFA1-4D0C-85BC-3C4EA8E5ABB0Q62031515-09D7A0DD-0D1D-4AA3-BFB4-EA56C1208B66Q62031869-997B7D5A-1E81-483D-B938-0C77DE9F5BDBQ63315781-FA3C24BA-C5A5-4444-A6FE-E7FA9E515FB1Q63321612-1D3D6EBB-66AC-4F93-8C1A-015B623FF115Q63334695-D7F77D6D-0B06-4767-BD6D-BC64B9E6873CQ63338889-E43B418D-F8EB-4C0B-B937-AE78A77A4D25Q63400571-DDB7B10F-795A-4C87-9FBD-7F15A5D2ED2DQ63400696-7B84F727-0D19-4E04-ACDE-A294736E87F5Q63405682-7AAB8833-7B4F-4C79-8619-7A47246EE570Q63592870-C92C4C67-8782-4407-93D5-107A5D2F1F74Q63812772-8E3C4FA4-664B-4019-A247-FBDEDE61B590Q63813345-B80C01FA-09D1-4D94-B876-27EDFF91B132Q63816594-5F2E6205-F894-47E5-AF91-2B949AB8FDB7Q63818051-46EE57DF-E66D-476C-8C31-2F8896420C5FQ63829161-D9C8DD01-7D2F-4DBB-9DB5-F0975F66D23EQ63834047-8AA56C08-9130-42A7-97E7-BE576E70F383Q63834578-5B02D22C-B647-4400-9838-F2AC6ACC931CQ63838502-2B58CADD-D559-4AA1-9BC3-386B97E80550Q63838719-1241B99D-5173-4FC6-8F7C-F910B6002A23Q63838958-5CC1C8EB-41CE-4B95-BA22-6ABE9B8A7F38Q63841347-2A4AB527-DA99-4DDD-8F69-0E3820446CE8
P4844
description
group of enantiomers
@en
para enancjomerów
@pl
name
Lumefantriini
@fi
Lumefantrin
@de
Lumefantrin
@sh
Lumefantrin
@sr
Lumefantrina
@es
Lumefantrina
@pt
Lumefantrine
@vi
Lumefantrină
@ro
lumefantrina
@it
lumefantrine
@en
type
label
Lumefantriini
@fi
Lumefantrin
@de
Lumefantrin
@sh
Lumefantrin
@sr
Lumefantrina
@es
Lumefantrina
@pt
Lumefantrine
@vi
Lumefantrină
@ro
lumefantrina
@it
lumefantrine
@en
altLabel
(+-)-2,7-dichloro-9-((Z)-P-chl ...... ino)methyl)fluorene-4-methanol
@en
(±)-2,7-dichloro-9-((Z)-p-chlorobenzylidene)-α-((dibutylamino)methyl)fluorene-4-methanol
@en
2-dibutylamino-1-[2,7-dichloro-9-(4-chloro-benzylidene)-9H-fluoren-4-yl]-ethanol
@en
2-dibutylamino-1-{2,7-dichloro ...... dene]-9H-fluoren-4-yl}-ethanol
@en
DL-benflumelol
@en
LUM566
@en
benflumetol
@en
benflumetol
@pl
dl-benflumelol
@en
prefLabel
Lumefantriini
@fi
Lumefantrin
@de
Lumefantrin
@sh
Lumefantrin
@sr
Lumefantrina
@es
Lumefantrina
@pt
Lumefantrine
@vi
Lumefantrină
@ro
lumefantrina
@it
lumefantrine
@en
P2868
P486
P592
P6366
P661
P662
P665
P683
P117
P1579
P2017
CCCCN(CCCC)CC(C1=C2C3=C(C=C(C=C3)Cl)/C(=C/C4=CC=C(C=C4)Cl)/C2=CC(=C1)Cl)O
P2067
527.154948
P2115
N0000178418
P2275
lumefantrine
@en
P231
82186-77-4